Alcon Inc. (ALC) Stock: Price, Forecast & Analyst Target
Alcon Inc. (ALC) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $74.52 (-0.98%), as of the Nov 19, 2026 trading session; market cap $35.8B.
Educational signal · not a buy or sell recommendation · How to read this
Alcon Inc. · ALC · NYSE · Healthcare · Medical - Specialties
Research dated 2026-09-12: Alcon sells eye-surgery systems, implantable lenses, procedure consumables, contact lenses and ocular-health products under the ALC ticker. Equipment comparisons are becoming harder just as newer products are expected to contribute more, making sustained sales momentum and recovery in reported operating profit the defining test.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Alcon (ALC)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $2.82B (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 6 of the last 8 reports
- Altman Z 2.83 · Piotroski F 8
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 80 | Strong | |
| 80 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $74.52 | |
| Change on the day | -0.98% | |
| 52-week range | $61.84–$87.64 | |
| Market capitalisation | $35.8B | — |
| Price / earnings (trailing) | 54.49 | |
| Shares traded on the day | 3.70M | |
| Beta (volatility vs the S&P 500) | 0.72 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Alcon (ALC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 14, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Alcon (ALC), and what does it report?
Short answer · as of
Alcon is an eye-care manufacturer with Surgical and Vision Care operations, not simply a medical-equipment vendor. A cataract procedure can involve its diagnostics, visualization systems or surgical platform, followed by demand for implantable lenses, solutions, instruments and custom packs; Vision Care adds replenishment demand from contact lenses and ocular-health products.
Research dated 2026-09-12.
Consolidated revenue therefore blends equipment purchases, procedure-linked products and repeat consumer use. That mix matters because hospital capital budgets, surgical activity and contact-lens demand can move differently, while research spending supports products across the portfolio.
What do the latest results show for Alcon (ALC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2.82B.
Research dated 2026-09-12.
The latest income statement shows revenue and gross profit rising from the preceding period, but research and development expense surged, selling and administrative expense also increased, and reported operating profit nearly disappeared. The earnings record simultaneously shows sales and per-share earnings above expectations, so the headline beat did not translate into comparable reported operating conversion.
Management expects harder equipment comparisons to be partly offset by more favorable contact-lens comparisons. It also expects TRYPTYR, Valeda, UNITY CS and PanOptix Pro in Europe to contribute more as the year progresses, while planned reinvestment of a government refund and a broadly stable selling-and-administrative burden relative to sales could limit near-term profit flow-through.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.82B | $0 | $0.00 (diluted) |
| Q1 FY2026 | $2.65B | $185M | $0.38 (diluted) |
| Q4 FY2025 | $2.72B | $217M | $0.44 (diluted) |
| Q3 FY2025 | $2.61B | $237M | $0.48 (diluted) |
What are the financial strengths and risks for Alcon (ALC)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive and exceeded capital spending throughout the reported window, giving Alcon internally generated funding despite uneven accounting profit. Annual revenue has advanced across successive reported periods, although the latest annual net result eased as research spending rose.
Debt substantially exceeds cash and short-term investments, even after long-term investments are included. Cash and short-term investments declined across the reported window, while the latest liquidity ratios indicate that short-term assets still cover short-term obligations; the strong quality screen does not remove the burden created by net debt and weak recent reported margins.
The business is most exposed when equipment demand slows while launch, research and commercial spending remain elevated. A rising annual dividend adds another recurring cash claim, so continued cash generation after capital spending matters more than the cash balance alone.
What should you watch next at Alcon (ALC)?
Short answer · as of
Current published price targets run low $35.00 · high $98.00 · consensus $78.39 · median $84.50 against a quoted price of $74.52 (as of Nov 19, 2026).
Research dated 2026-09-12.
Watch whether UNITY CS, TRYPTYR, Valeda and PanOptix Pro produce visible sales contributions while contact-lens comparisons improve. Those gains need to offset harder equipment comparisons without requiring selling and administrative spending to consume the benefit.
Reported operating conversion deserves particular attention after gross profit rose but operating profit nearly vanished. The scheduled earnings release can also test whether sales and per-share earnings continue to clear expectations and whether consensus assumptions for longer-run expansion remain plausible.
Cash flow offers the cleanest cross-check: operating cash should continue to cover capital spending, while cash and short-term investments should stabilize rather than extending their decline.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Alcon compare with its peers?
Short answer
Alcon's score ranks 4th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Alcon combines capital equipment, procedure-specific consumables and implantable lenses with a separate contact-lens and ocular-health franchise. A pure equipment maker depends more directly on purchasing cycles, while a pure contact-lens business lacks Alcon’s exposure to surgical procedures and the associated demand for lenses, packs, solutions and instruments.
That breadth creates distinct demand rhythms inside the same company: equipment purchases can be intermittent, procedure products move with surgical activity, and Vision Care products depend more on replenishment. The mix can cushion weakness in a product category, but it can also leave strong sales growth paired with poor operating conversion when development and commercial spending rise.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| Alcon (ALC) — this page | $74.52 | $35.8B | 80 |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $1.12 Nov 18, 2026 | $75.1M | 45 5-pillar Nov 18, 2026 | |
| $20.65 Nov 18, 2026 | $432M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $35.00 – $98.00
- Consensus target
- $78.39
- Median target
- $84.50
Consensus record · Captured .
Measured against a quoted price of $74.52 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ALC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About ALC (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do UNITY CS and PanOptix Pro fit into Alcon’s growth plan?
UNITY CS expands Alcon’s cataract-surgery equipment offering, while PanOptix Pro adds to its implantable-lens portfolio. Management expects their launch contributions to become more meaningful as the year progresses.
Why do equipment and contact-lens comparisons pull Alcon in different directions?
Equipment demand reflects purchasing cycles for surgical systems, whereas contact lenses depend on repeat use and replenishment. Management expects harder equipment comparisons alongside more favorable contact-lens comparisons.
Why did Alcon’s reported operating profit weaken while gross profit rose?
Research and development expense increased sharply and selling and administrative expense also rose, absorbing the higher gross profit. The result was a steep deterioration in reported operating conversion despite higher revenue.
Does Alcon’s surgical model generate cash after capital spending?
Operating cash flow exceeded capital spending throughout the reported window. That cash generation is important because debt remains above cash and investments, while cash and short-term investments have declined.
What is the ALC stock price today?
The last price recorded for Alcon Inc. (ALC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALC price target?
The analyst consensus price target for Alcon Inc. (ALC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com